A panel of oncology experts examine the role of consolidation immunotherapy in patients receiving concurrent chemoradiotherapy for unresectable Stage-III NSCLC, discussing 5-year survival outcomes from the PACIFIC trial, the impact on institutional treatment approaches, criteria for selecting patients for consolidation durvalumab, the significance of baseline scans, as well as exploring real-world evidence on consolidation durvalumab.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.